Background: Stenosis of the venous connections and conduits is a well-known late complication of the Fontan procedure. Currently, data on the outcomes of percutaneous intervention for the treatment of extra-or intracardiac conduits and lateral tunnel baffles obstruction are limited. In an attempt to better define the nature and severity of the stenosis and the results of catheter interventional management, we reviewed Fontan patients with obstructed extra-or intracardiac conduits and lateral tunnel baffles. Methods: Retrospective review of all Fontan patients who had cardiac catheterization from January 2002 to October 2018 was performed. Hemodynamic and angiographic data that assessed extra-or intracardiac conduit, or lateral tunnel baffle obstruction/stenosis were evaluated. Results: Twenty patients underwent catheter intervention because of conduit stenosis, including calcified homografts, stenotic Gore-Tex conduits and obstructed lateral tunnels. Six other patients had Fontan obstruction but were referred for surgical revision. After stenting, there was a significant reduction in the connection gradient [2.0 mm Hg (IQR 2; 3) vs 0 mm Hg (IQR 0; 1), P < .0001]. Fontan conduit/connection diameter increased [10.5 mm (IQR 9; 12) vs 18 mm (IQR 14.9; 18); P < .0001] and New York Heart Association class [III (IQR II; III) vs I (IQR II; III); P = .03) with stent placement.
| INTRODUC TI ON
Since Fontan and Baudet originally described the Fontan palliation of tricuspid atresia in 1971, 1 there have been many modifications to the operation. With the concept of conservation of energy, de Leval et al 2 confirmed the best model to be of the total cavopulmonary connection, utilizing either the lateral tunnel or eventually the intraor extracardiac conduit (ECC).
The lateral tunnel is not commonly performed because of increased incidence of arrhythmia, and one report 3 noted a significant incidence of lateral tunnel stenosis. However, the fate of ECC has not been clearly defined in long-term studies. Most postoperative studies have focused primarily on mortality or the need for early reoperation. Several studies evaluated modification of the orientation and placement of the ECC to maximize energy conservation and provide equal bilateral pulmonary artery flow distribution. 4 They reported an optimal size for the ECC of 18-20 mm diameter based on flow dynamics during catheterization. There are concerns that in patients younger than 3 years old, the use a large bore (18 mm) conduit will not fit small patient vasculature. 5, 6 Often a 14, 16, or 18 mm conduit has been used for repair. One study reported a high incidence of Dacron conduit stenosis for ECC in Fontan patients. 7 Another report described stenting of Dacron ECC noting the morphology of different stenoses. 8 They reported thick neo-intima in Dacron grafts. Because of the significant incidence of neointimal peel, Dacron grafts have been abandoned. Improved results have been reported with the routine use of Gore-Tex tubes (W. L. Gore and Associate Inc., Flagstaff, Arizona) usually of 18 or 20 mm diameter. 8 Recently long-term Fontan follow-up reports have noted chronic liver failure and cirrhosis as progressive events in Fontan survivors. 9 While pulmonary artery (PA) hypoplasia and stenosis have been recognized and treated in postoperative Fontan patients, the long-term fate of the inferior vena cava (IVC) conduit itself is often overlooked.
Several studies have noted the occurrence of conduit stenosis requiring surgical conversion, 10 but the mechanism of the conduit failure has not been accurately investigated.
Late results in 1138 Fontan patients at the Mayo Clinic were recently reviewed. 11 We wished to focus on Fontan patients sent to the cardiac catheterization laboratory to define postoperative hemodynamics and to define potential etiologies for Fontan failure. The aim of this report is to define the hemodynamics and mechanisms of IVC conduit obstruction and describe successful treatment of Fontan conduit obstruction with intravascular stent placement.
| ME THODS
We reviewed 233 patients after Fontan who had diagnostic cardiac catheterization at Mayo Clinic, Rochester, Minnesota between January 2002 and October 2018. Patients who had superior vena cava (SVC) stenosis, pulmonary artery balloon dilation/stenting, or atriopulmonary/right ventricle connection stenosis were excluded.
One patient who had had Fontan procedure and previously undergone catheterization at our institution but underwent stenting by one of authors (D.J.H.) elsewhere was also included in the analyses. We identified 28 patients with obstruction of the Fontan IVC conduit. Two patients who had not provided research authorization were excluded. The final cohort included 26 patients, 6 of these patients were referred to surgery for conduit revision because of other surgical indications. The purpose of this report was to review the hemodynamic findings and interventional treatment of 20 patients with intracardiac or extracardiac conduit or lateral tunnel stenosis.
Clinical, hemodynamic, and angiographic data were reviewed.
Patients were indexed by the first catheterization in which a stent was implanted into the stenotic Fontan connection or conduit.
Angiographic and hemodynamic assessments were made prior to the decision for catheter intervention. Angiographic descriptions and measurements were obtained from the operator's observations during the procedure and/or from prior radiologic computerized tomography (CT) or magnet resonance imaging (MRI) data. When possible, measurements were obtained from the anterior-posterior and lateral angiographic projections. The minimum stenotic dimensions were recorded and the type and location and apparent mechanism of the stenosis defined. One or more stents were deployed using 
| RE SULTS

| Hemodynamics
The catheterization hemodynamics varied based on age after Fontan completion, severity of stenosis and presenting symptoms.
Overall hemodynamic data are presented in Table 1 and the details of hemodynamics and stenting in each patient are outlined in Table 2 . Mean Fontan conduit pressure >15 mm Hg was present in 44% adults (age ≥18) and 30% of the pediatric patients. Moreover, older patients with significant associated symptoms of edema and protein-losing enteropathy (PLE) uniformly had elevated Fontan pressures. There was a significant reduction in the connection gradient from a prestent median gradient of 2 mm Hg (2; 3) to a poststent median gradient of 0 mm Hg (0; 1), P < .0001.
| Stenting
Various bare metal stents were utilized for enlargement of the stenosis in 15 of the cases with a final diameter of 14-20 mm. covered Cheatham Platinum stent was placed in six patients. In one patient with a lateral tunnel Fontan (Figure 1 ), a covered stent was used to avoid risk for development of right to left shunt and in the remaining patients it was used to protect against disruption of a calcified, stenotic homograft. In six patients, multiple stents were implanted at the same intervention (Figures 2, 4, and 5). Two patients had implantation of a second stent at a later catheterization, and three patients had subsequent redilation of a previous stent.
Homograft conduits were found to have diffuse calcification in addition to severe stenosis at the IVC or pulmonary artery ends of the conduit. Figure 3 illustrates diffuse calcific (13 mm) stenosis of a 20-mm homograft conduit placed 20 years earlier. Two 4010 Palmaz stents dilated the conduit successfully to 18 mm. Figure 4 illustrates diffuse central stenosis of a 14-mm Gore-Tex ECC originally placed at age 2 years. Sixteen years later the conduit is stretched causing diffuse narrowed to 12 mm. After placement of two 4010 Palmaz stents, with high pressure balloon dilation to 18 mm, the final conduit diameter averaged 17 mm. One other patient had successful dilation of a Gore-Tex conduit from 3 to 14 mm with improvement of PLE symptoms. Figure 5 illustrates findings in a 23-year-old patient with diffuse, proximal, and distal stenosis of an 18-mm Gore-Tex ECC with stenosis of 10-12 mm. The entire conduit was stented with three 36-mm long bare metal stents placed with an 18 mm BIB balloon. The stents were then further dilated to 19-mm with a 20-mm Atlas balloon at 14 ATM. High pressure balloon dilation was necessary in both calcified homografts and the Gore-Tex conduits. Figure 6 illustrates two examples of focal stenosis of calcified homograft conduits which appear to be secondary to patient growth and stretch at the end of the conduit. The stenosis was effectively relieved with placement of covered CP stents. Figure 7 illustrates the statistically significant increase in Fontan conduit or connection diameters with percutaneous stent placement [10.5 mm (IQR 9; 12) prestenting vs 18 mm (IQR 14.9; 18) poststenting; P < .0001].
| Adverse events and follow-up in patients undergoing percutaneous intervention
There were no serious adverse events noted in any of the patients who underwent catheter intervention. There were two patients who had a small extravasation of contrast after stent placement in that Gore-Tex ECC conduits can be effectively dilated and stented.
| D ISCUSS I ON
In addition, a unique aspect of our review compared to previous studies focusing on stenting of Fontan conduit obstruction is that most of the patients were considerably older and were found to have significant obstruction many years after the initial Fontan procedure (median 12 years).
Several of the older patients in this study were sent to catheterization for evaluation of hepatic cirrhosis and had not been previously We noted that there was a higher prevalence of male subjects who had conduit obstruction requiring stent placement. Although, this may partially related to male preponderance in our Fontan population, this number is higher than previously report in the Mayo Clinic cohort (61% males). Male predominance was also present in the Boston study describe the outcomes of stenting in lateral tunnels. 3 Whether male patients are more prone to developing Fontan obstruction deserves further investigation. Figure 5 ). Thus, it is not surprising to find that the 18 mm Gore-Tex ECC later is only 12 or 14 mm in diameter. We did not observe evidence of thrombosis of the Gore-Tex conduit. W. L. Gore laboratories now report the availability of new Gore-Tex 12 Stretch conduits 14-24 mm in diameter and up to 40 cm in length which will stretch while retaining its original internal diameter. This would appear to offer a significant advantage in the future for Fontan ECCs. However, we feel strongly that even Gore-Tex conduits should be reassessed for conduit obstruction at least 10 years after implantation and periodically thereafter.
In summary, in this study we have observed that severely narrowed and stretched Gore-Tex tubes can be effectively stented to dilate them back to their original 18-20 mm dimensions. While multiple, heavy duty stents and high pressure dilation may be necessary to achieve these results, they seem safe and effective as observed in our patients.
| Limitations
This study is limited by the small cohort of patients who had stenting of their Fontan IVC conduits. Multicenter studies and reports may help to corroborate our observations. The sample size limited our ability to perform additional statistical analyses and regression analyses to predict stenosis. It is particularly noted that many Fontan patients have been lost to effective follow up or have not had an assessment of their IVC conduit.
| CON CLUS IONS
We present our findings in a group of Fontan patients who had obstruction of their Fontan IVC to PA pathway. Our results demonstrate that stenting of stenotic Fontan conduits can be safely performed, eliminating conduit obstruction of both calcified homograft and stenotic Gore-Tex ECC. While not all stents were fully dilated to 18-20 mm, we would expect that 18-20 mm conduits should be the goal of such procedures in most cases. In some cases, use of a covered stent may be advantageous to avoid potential risk for conduit disruption particularly with the calcified homograft conduit. Earlier recognition of high atrial pressures or minor degrees of ECC conduit obstruction may halt progression of hepatic fibrosis and cirrhosis. Lastly, by demonstrating that conduit obstruction can occur with time and growth in any Fontan conduit, we hope to emphasize earlier and repeated assessment of conduit adequacy and patency.
